KIORA PHARMACEUTICALS INC
KPRX · XNASCIK 1372514fmd_0DWMTAHK9SAX331DTEJZP073P9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 51 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 0 | 2 | 3 | 0 | 0 | – | 0 | 16 | 0 |
| Research and development | 8 | 10 | 8 | 5 | 4 | 5 | 3 | 4 | 8 | 11 |
| Total operating expenses | 14 | 15 | 12 | 10 | 7 | 14 | 12 | 13 | 12 | 13 |
| Operating income | – | – | (11) | – | (7) | (14) | (12) | (13) | 5 | (13) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Other non-operating income (expense) | 0 | (0) | 0 | 0 | 0 | 0 | (1) | 0 | 1 | 1 |
| Income before taxes | (13) | (15) | (11) | (7) | (7) | (14) | (14) | (12) | 6 | (12) |
| Income tax expense | 0 | (1) | 0 | 0 | 0 | (0) | (0) | 0 | 2 | (1) |
| Net income from continuing operations | (13) | (13) | (11) | (7) | (7) | (14) | (14) | (13) | 4 | (11) |
| Net income | (13) | (13) | (11) | (7) | (7) | (14) | (14) | (13) | 4 | (11) |
| Net income to common shareholders | (13) | – | – | – | – | – | – | – | – | – |